Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

Garnero P, Delmas PD (2001) Biochemical markers of bone turnover in osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, vol 2. Academic Press, San Diego, pp 459–477 Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929−1936 Ross PD, Kress BC, Parson RE et al. (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11:76−82 van Daele PLA, Seibel MJ, Burger H et al. (1996) Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 312:482−483 Garnero P, Hausherr E, Chapuy M-C et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 11:1531−1538 Hansen MA, Overgaard K, Riis BJ, Christiansen C (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 303:961−964 Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526−1536 Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes with fracture as endpoint. Endocr Rev 23:16−37 Hochberg MC, Ross PD, Black D et al. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246−1254 Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metab 85:231−236 Siris ES, Miller PD, Barrett-Connor E et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 286:2815−2822 Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254−1259 Ravn P (2001) Prediction of response in bone mass by biochemical markers of bone turnover during antiresorptive therapy for prevention of osteoporosis. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives; Martin Dunitz, London, pp 167−178 Gundberg CM (2001) Osteocalcin. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives. Martin Dunitz, London; pp 65−72 Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026 Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541 Cummings SR, Black DM, Thompson DE et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. JAMA 280:2077–2082 Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352 Reginster J, Minne HW, Sorenson OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91 McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340 Schnitzer T, Bone HG, Crepaldi G et al. (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1–12 Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871−1878 Thiébaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298−307 Reid IR, Brown JP, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653−661 Kendler DL, Diez-Perez A, Gaines KA, Verbruggen N, Melton ME (2002) Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study. Osteoporos Int 13:S32 (Abstract P92SA) Palmisano J, Melton M, Lewiecki EM et al. (2002) Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis. Osteoporos Int 13:S36 (Abstract P103MO) Chesnut III CH, Skag A, Christiansen C et al. (2004) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a between-dose interval greater than 2 months: results from the BONE study. J Bone Miner Res (in press) Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD (1996) Increased bone turnover in late menopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349 Russell RGG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9:S66−S80 Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693−1700 Harris ST, Gertz BJ, Genant HK et al. (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399−1406 Harris ST, Eriksen EF, Davidson M et al. (2001) Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890−1897 Raisz L, Smith JA, Trahiotis M et al. (2000) Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 11:615−620 Reginster JY, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83−91 Eastell R, Barton I, Hannon RA et al. (2003) Relationship of early changes in bone resorption to reduction of fracture risk with risedronate. J Bone Miner Res 18:1051–1056 Bauser DC, Black DM, Garnero P et al. (2000) Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: the Fracture Intervention Trial. Osteoporos Int 13:521